Document:

Exhibit 10.10

 

 

AMENDMENT NO. 1

to

WARRANT TO PURCHASE COMMON
STOCK

 

THIS AMENDMENT SHOULD
BE ATTACHED TO THE ORIGINAL WARRANT

 

This Amendment No. 1 to Warrant
to Purchase Common Stock (this “Amendment”) is made this 9th day of January, 2012 by and between Emmaus Life
Sciences, Inc., a Delaware corporation (the “Company”) and Gregoire De Rothschild, an individual (the “Warrantholder”).
Capitalized terms used herein and not defined shall have the meanings given to them in the Warrant (as defined below).

 

W I T N E S S E T H:

 

WHEREAS, the Company issued
a Warrant to Purchase Common Stock to the Warrantholder on August 31, 2011 to purchase up to an aggregate of 275,482 shares of
the Company’s Common Stock at an exercise price of $1.00 per share (the “Warrant”);

 

WHEREAS, the Company and
the Warrantholder desire to amend the Warrant by entering into this Amendment; and

 

WHEREAS, Section 17 of the
Warrant permits an amendment of the Warrant upon the prior written consent of the Company and the Warrantholder.

 

NOW, THEREFORE, in consideration
of the foregoing, which is incorporated herein by reference, and other good and valuable consideration, the receipt and adequacy
of which are hereby acknowledged, the Company and the Warrantholder, intending to be legally bound hereby, agree to amend the Warrant
as follows:

 

1.           Section
3(b) of Warrant. Section 3(b) of the Warrant shall be deleted and replaced in its entirety with the following:

 

“(b)       Termination
upon Certain Events. In connection with the Company’s proposed public offering of its securities pursuant to a registration
statement on Form S-1 (333-175434) filed with the Securities and Exchange Commission on July 11, 2011, if the Financial Industry
Regulatory Authority deems the underwriters’ compensation to be unreasonable, then this Warrant will terminate.”

 

2.           Miscellaneous.

 

(a)           To
the extent there is any conflict between the terms of the Warrant and the terms hereof, the terms of this Amendment shall take
precedence.

 

(b)           Except
as herein amended, the Warrant shall remain unchanged and in full force and effect. Each and every term, covenant and condition
of the Warrant, not specifically preempted hereby, is incorporated herein such that the Warrant and this Amendment thereto shall
be read and construed as one instrument.

 

(c)           This
Amendment shall be governed by, and construed in accordance with, the internal laws of the State of California, without reference
to the choice of law provisions thereof.

 

    	1

    	 

    

 

(d)           This
Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective heirs, legatees, assigns and
transferees, as the case may be.

 

[Remainder of page intentionally
left blank.]

 

    	2

    	 

    

 

In
Witness Whereof, the Company and the Warrantholder have caused this Amendment to be duly executed as of the date first
above written.

 

	 	“COMPANY”
	 	 	 
	 	Emmaus Life Sciences, Inc.,
	 	a Delaware corporation
	 	 	 
	 	By:	/s/ Yutaka Niihara
	 	Name:  Yutaka Niihara
	 	Title:    President and Chief Executive Officer
	 	 	 
	 	“WARRANTHOLDER”
	 	 	 
	 	/s/ Gregoire De Rothschild
	 	Gregoire De Rothschild

 

 

3Exhibit 4.19

 

 

THIS WARRANT AND THE SECURITIES
ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD,
OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED
UNDER SUCH ACT OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SUCH ACT.

 

	Date of Issuance:	Void after:
	 	 
	January 17, 2012	January 17, 2015

 

EMMAUS LIFE SCIENCES, INC.

 

Warrant
to Purchase Shares of

Common
Stock

 

FOR VALUE RECEIVED, Hope
International Hospice, Inc. (“Holder”), is entitled to purchase from the Company, subject to the provisions
of this Warrant (“Warrant”), from Emmaus Life Sciences, Inc., a Delaware corporation (“Company”),
at any time not later than 5:00 P.M., Pacific Time on January 17, 2015 (the “Expiration Date”), 55,556 shares
(the “Warrant Shares”) of the Company’s Common Stock, par value $0.001 per share (“Common Stock”)
at a price per share equal to $1.00 (the “Exercise Price”). The Exercise Price and the number of Warrant Shares purchasable
upon exercise of this Warrant shall be subject to adjustment from time to time as described herein.

 

1.           Method
of Exercise.

 

(a)           Subject
to compliance with the terms and conditions of this Warrant and applicable securities laws, this Warrant may be exercised, in whole
or in part at any time or from time to time, on or before the Expiration Date by the delivery (including, without limitation, delivery
by facsimile) of the form of Notice of Exercise attached hereto as Exhibit A (the “Notice of Exercise”),
duly executed by the Holder, at the principal office of the Company, and as soon as practicable after such date, surrendering:

 

(i)           this
Warrant at the principal office of the Company, and

 

(ii)           payment,
(i) in cash (by check) or by wire transfer, (ii) by cancellation by the Holder of indebtedness of the Company to the Holder; or
(iii) by a combination of (i) and (ii), of an amount equal to the product obtained by multiplying the number of shares of Common
Stock being purchased upon such exercise by the then effective Exercise Price (the “Exercise Amount”):

 

(b)           Each
exercise of this Warrant shall be deemed to have been effected immediately prior to the close of business on the day on which this
Warrant is surrendered to the Company as provided above. The person or persons entitled to receive the Warrant Shares issuable upon exercise of
this Warrant shall be treated for all purposes as the holder of record of such Warrant Shares as of the close of business on the
date the Holder is deemed to have exercised this Warrant.

 

    	

    	 

    

 

(c)           As
soon as practicable after the exercise of this Warrant in whole or in part, the Company at its expense will cause to be issued
in the name of, and delivered to, the Holder, or as such Holder (upon payment by such Holder of any applicable transfer taxes)
may direct:

 

(i)           a
certificate or certificates for the number of Warrant Shares to which such Holder shall be entitled, and

 

(ii)           in
case such exercise is in part only, a new warrant or warrants (dated the date hereof) of like tenor, calling in the aggregate on
the face or faces thereof for the number of Shares equal to the number of such Warrant Shares described in this Warrant minus the
number of such Warrant Shares purchased by the Holder upon all exercises made in accordance with this Section 1.

 

2.           Representations
and Warranties of the Company. 

 

In connection with the transactions
provided for herein, the Company hereby represents and warrants to the Holder that:

 

(a)           Organization,
Good Standing, and Qualification. The Company is a corporation duly organized, validly existing, and in good standing under
the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business as now conducted.
The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify
would have a material adverse effect on its business or properties.

 

(b)           Authorization.
Except as may be limited by applicable bankruptcy, insolvency, reorganization or similar laws relating to or affecting the enforcement
of creditors’ rights, all corporate action has been taken on the part of the Company, its officers and directors necessary
for the authorization, execution and delivery of this Warrant. The Company has taken all corporate action required to make all
the obligations of the Company reflected in the provisions of this Warrant the valid and enforceable obligations they purport to
be. The issuance of this Warrant will not be subject to preemptive rights of any stockholders of the Company. The Company has authorized
sufficient shares of Common Stock to allow for the exercise of this Warrant.

 

3.           Representations
and Warranties of the Holder. In connection with the transactions provided for herein, the Holder hereby represents and
warrants to the Company that:

 

(a)           Authorization.
Holder represents that it has full power and authority to enter into this Warrant. This Warrant constitutes the Holder’s
valid and legally binding obligation, enforceable in accordance with its terms, except as may be limited by (i) applicable bankruptcy,
insolvency, reorganization, or similar laws relating to or affecting the enforcement of creditors’ rights and (ii) laws relating
to the availability of specific performance, injunctive relief or other equitable remedies.

 

    	- 2 -

    	 

    

 

(b)           Purchase
Entirely for Own Account. The Holder acknowledges that this Warrant is entered into by the Holder in reliance upon such Holder’s
representation to the Company that the Warrant and the Warrant Shares (collectively, the “Securities”) will
be acquired for investment for the Holder’s own account, not as a nominee or agent, and not with a view to the resale or
distribution of any part thereof, and that the Holder has no present intention of selling, granting any participation in or otherwise
distributing the same. By acknowledging this Warrant, the Holder further represents that the Holder does not have any contract,
undertaking, agreement, or arrangement with any person to sell, transfer or grant participations to such person or to any third
person, with respect to the Securities.

 

(c)           Disclosure
of Information. The Holder acknowledges that it has received all the information it considers necessary or appropriate for
deciding whether to acquire the Securities. The Holder further represents that it has had an opportunity to ask questions and receive
answers from the Company regarding the terms and conditions of the offering of the Securities.

 

(d)           Investment
Experience. The Holder is an investor in securities of companies in the development stage and acknowledges that it is able
to fend for itself, can bear the economic risk of its investment, and has such knowledge and experience in financial or business
matters that it is capable of evaluating the merits and risks of the investment in the Securities. If other than an individual,
the Holder also represents it has not been organized solely for the purpose of acquiring the Securities.

 

(e)           Accredited
Investor. The Holder is an “accredited investor” within the meaning of Rule 501 of Regulation D, as presently in
effect, as promulgated by the Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933,
as amended (the “Act”).

 

(f)           Restricted
Securities. The Holder understands that the Securities are characterized as “restricted securities” under the federal
securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that
under such laws and applicable regulations such securities may be resold without registration under the Act, only in certain limited
circumstances. In this connection, Holder represents that it is familiar with Rule 144, as presently in effect, as promulgated
by the SEC under the Act (“Rule 144”), and understands the resale limitations imposed thereby and by the Act.

 

(g)           Further
Limitations on Disposition. The Holder, by acceptance hereof, agrees that, absent an effective registration statement filed
with the SEC under the Act covering the disposition or sale of this Warrant or the Warrant Shares issued or issuable upon exercise
hereof, as the case may be, and registration or qualification under applicable state securities laws, such Holder will not sell,
transfer, pledge, or hypothecate any or all of this Warrant or such Warrant Shares, as the case may be, unless either (i) the Company
has received an opinion of counsel, in form and substance reasonably satisfactory to the Company, to the effect that such registration
is not required in connection with such disposition or (ii) the sale of such Securities is made pursuant to SEC Rule 144.

 

    	- 3 -

    	 

    

 

(h)           Legends.
It is understood that the Securities may bear the following or a similar legend:

 

“THESE SECURITIES
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED,
OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR
AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER SUCH ACT OR UNLESS SOLD PURSUANT TO RULE
144 UNDER SUCH ACT.”

 

4.           Valid
Issuance; Taxes. All Warrant Shares issued upon the exercise of this Warrant shall be validly issued, fully paid and nonassessable,
and the Company shall pay all taxes and other governmental charges that may be imposed in respect of the issue or delivery thereof.
The Company shall not be required to pay any tax or other charge imposed in connection with any transfer involved in the issuance
of any certificate for Warrant Shares in any name other than that of the Holder of this Warrant, and in such case the Company shall
not be required to issue or deliver any stock certificate or security until such tax or other charge has been paid, or it has been
established to the Company’s reasonable satisfaction that no tax or other charge is due.

 

5.           Adjustment
of Exercise Price and Number and Kind of Warrant Shares. The number and kind of Warrant Shares purchasable upon exercise of
this Warrant and the Exercise Price shall be subject to adjustment from time to time as follows:

 

(a)           Subdivisions,
Combinations and Other Issuances. If the Company shall at any time after the issuance but prior to the expiration of this Warrant
subdivide its Common Stock, by split-up or otherwise, or combine its Common Stock, or issue additional shares of its Common Stock
as a dividend with respect to any shares of its Common Stock, the Exercise Price shall be proportionally decreased and the number
of Warrant Shares issuable on the exercise of this Warrant shall be proportionately increased in the case of a subdivision or stock
dividend. The Exercise Price shall be proportionally increased and the number of Warrant Shares issuable on the exercise of this
Warrant shall be proportionately decreased in the case of a combination. Any adjustment under this Section 5(a) shall become effective
at the close of business on the date the subdivision or combination becomes effective, or as of the record date of such dividend,
or in the event that no record date is fixed, upon the making of such dividend.

 

    	- 4 -

    	 

    

 

(b)           Reclassification,
Reorganization and Consolidation. In case of any reclassification, capital reorganization or change in the capital stock of
the Company (other than as a result of a subdivision, combination or stock dividend provided for in Section 5(a) above), then,
as a condition of such reclassification, reorganization or change, lawful provision shall be made, and duly executed documents
evidencing the same from the Company or its successor shall be delivered to the Holder, so that the Holder shall have the right
at any time prior to the expiration of this Warrant to purchase, at a total price equal to that payable upon the exercise of this
Warrant, the kind and amount of shares of stock and other securities or property receivable in connection with such reclassification,
reorganization or change by a holder of the same number and type of securities as were purchasable as Warrant Shares by the Holder
immediately prior to such reclassification, reorganization or change. In any such case appropriate provisions shall be made with
respect to the rights and interest of the Holder so that the provisions hereof shall thereafter be applicable with respect to any
shares of stock or other securities or property deliverable upon exercise hereof, and appropriate adjustments shall be made to
the per-share Exercise Price payable hereunder, provided the aggregate Exercise Price shall remain the same.

 

(c)           Notice
of Adjustment. When any adjustment is required to be made in the number or kind of Warrant Shares purchasable upon exercise
of the Warrant, or in the Exercise Price, the Company shall promptly notify the Holder of such event and of the new Exercise Price
and number of Warrant Shares or other securities or property thereafter purchasable upon exercise of this Warrant.

 

6.           No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant, but in lieu of such fractional shares the Company shall make a cash payment therefor on the basis of the Exercise
Price then in effect.

 

7.           No
Stockholder Rights. Prior to exercise of this Warrant, the Holder shall not be entitled to any rights of a stockholder with
respect to the Warrant Shares, including (without limitation) the right to vote such Warrant Shares, receive dividends or other
distributions thereon, exercise preemptive rights or be notified of stockholder meetings, and, except as otherwise provided in
this Warrant, such Holder shall not be entitled to any stockholder notice or other communication concerning the business or affairs
of the Company.

 

8.           Restrictions
on Transfer. As provided herein, this Warrant may be transferred only pursuant to a registration statement filed under the
Act, or an exemption from such registration. Subject to such restrictions, the Company shall transfer this Warrant from time to
time upon the books to be maintained by the Company for that purpose, upon surrender hereof for transfer, properly endorsed or
accompanied by appropriate instructions for transfer and such other documents as may be reasonably required by the Company, including,
if required by the Company, an opinion of its counsel to the effect that such transfer is exempt from the registration requirements
of the Act, to establish that such transfer is being made in accordance with the terms hereof, and a new Warrant shall be issued
to the transferee and the surrendered Warrant shall be canceled by the Company.

 

9.           Governing
Law; Consent to Jurisdiction; Waiver of Jury Trial. This Warrant shall be governed by and construed under the laws of the State
of California as applied to agreements among California residents, made and to be performed entirely within the State of California.
The Company and, by accepting this Warrant, the Holder, each irrevocably submits to the exclusive jurisdiction of the courts of
the State of California located in Los Angeles

 

    	- 5 -

    	 

    

 

County and the United States
District Court for the Central District of California for the purpose of any suit, action, proceeding or judgment relating to or
arising out of this Warrant and the transactions contemplated hereby. Service of process in connection with any such suit, action
or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices
under this Warrant. The Company and, by accepting this Warrant, the Holder, each irrevocably consents to the jurisdiction of any
such court in any such suit, action or proceeding and to the laying of venue in such court. The Company and, by accepting this
Warrant, the Holder, each irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought
in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought
in an inconvenient forum. EACH OF THE COMPANY AND, BY ITS ACCEPTANCE HEREOF, THE HOLDER HEREBY WAIVES ANY RIGHT TO REQUEST A
TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS WARRANT AND REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO
THIS WAIVER.

 

10.           Successors
and Assigns. The terms and provisions of this Warrant shall inure to the benefit of, and be binding upon, the Company and the
holders hereof and their respective successors and assigns.

 

11.           Titles
and Subtitles. The titles and subtitles used in this Warrant are used for convenience only and are not to be considered in
construing or interpreting this Warrant.

 

12.           Notices.
Unless otherwise provided, any notice required or permitted under this Warrant shall be given in writing and shall be deemed
effectively given as hereinafter described (a) if given by personal delivery, then such notice shall be deemed given upon such
delivery, (b) if given by telex or facsimile, then such notice shall be deemed given upon receipt of confirmation of complete transmittal,
(c) if given by mail, then such notice shall be deemed given upon the earlier of (i) receipt of such notice by the recipient or
(ii) three days after such notice is deposited in first class mail, postage prepaid, and (d) if given by an internationally recognized
overnight air courier, then such notice shall be deemed given one business day after delivery to such carrier. All notices shall
be addressed as follows: if to the Holder, at its address as set forth in the Company’s books and records and, if to the
Company, at the address as follows, or at such other address as the Holder or the Company may designate by ten days’ advance
written notice to the other:

 

If to the Company:

Emmaus Life Sciences, Inc.

20725 South Western Avenue,
Suite 136

Torrance, CA 90501

Attn: Yasushi Nagasaki, Chief
Financial Officer

Fax: (310) 214-0075

 

    	- 6 -

    	 

    

 

With a copy to:

K&L Gates

10100 Santa Monica Boulevard
Seventh Floor

Los Angeles, CA 90067

Attn: Katherine J. Blair

Fax: (310) 552-5001

 

13.           Expenses.
If any action at law or in equity is necessary to enforce or interpret the terms of this Warrant, the prevailing party shall
be entitled to reasonable attorneys’ fees, costs and necessary disbursements in addition to any other relief to which such
party may be entitled.

 

14.           Entire
Agreement; Amendments and Waivers. This Warrant and any other documents delivered pursuant hereto constitute the full and entire
understanding and agreement between the parties with regard to the subjects hereof and thereof. Nonetheless, any term of this Warrant
may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and
either retroactively or prospectively), with the written consent of the Company and the Holder; or if this Warrant has been assigned
in part, by the holders or rights to purchase a majority of the shares originally issuable pursuant to this Warrant.

 

15.           Severability.
If any provision of this Warrant is held to be unenforceable under applicable law, such provision shall be excluded from this
Warrant and the balance of the Warrant shall be interpreted as if such provision were so excluded and shall be enforceable in accordance
with its terms.

 

    	- 7 -

    	 

    

 

IN WITNESS WHEREOF, the
parties have executed this Warrant as of the date above written.

 

	 	EMMAUS LIFE SCIENCES, INC.
	 	 	 
	 	By:	/s/ Willis C. Lee
	 	Name:  Willis C. Lee
	 	Title:    Chief Operating Officer

 

    	- 8 -

    	 

    

 

EXHIBIT A

 

Notice
of Exercise

 

EMMAUS LIFE SCIENCES, INC.

 

Attention: Chief Financial
Officer

 

The undersigned hereby elects
to purchase, pursuant to the provisions of the Warrant, as follows:

 

 ________shares
of Common Stock pursuant to the terms of the attached Warrant at $_______ per share (the applicable Exercise Price as of the date
of this Notice of Exercise) , and tenders herewith payment in cash of the Exercise Price of such Warrant Shares in full, together
with all applicable transfer taxes, if any.

 

The undersigned hereby represents
and warrants that Representations and Warranties in Section 3 of the Warrant are true and correct as of the date hereof.

 

HOLDER:

 

	Date: _____________________________	 	By: _______________________________________
	 	 	Name: _____________________________________
	 	 	Address: ___________________________________
	 	 	__________________________________________ 
	 	 	__________________________________________ 
	 	 	 
	Name in which shares should be registered:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}]]